OIS@AAO

Few can track the past 10 years of advances in glaucoma treatment as well as Andrew Iwach, MD, executive director of the Glaucoma Center of…

Dan Myers, CEO of Alimera Sciences, says company growth is moving the firm into cash-positive territory in 2018. What challenges did he have to conquer…

Christian Roesky, PhD, CEO and managing director of Novaliq GmbH, explains how the company’s water-free ophthalmic therapies can bring new treatments to ophthalmology’s most vexing…

Joe Boorady, OD, president & CEO of TearScience, details the rollout of the company’s dry eye suite of tools now that it’s part of Johnson…

Tom Gadek, president and CEO of dry eye start-up TearSolutions, explains how his “religious vision quest” at SARcode Bioscience, the entity that developed the drug…

Iconic Therapeutics is looking to take a significant step in ophthalmology in 2018, William Greene, MD, CEO, said during the Company Showcase 3 session at…

Jonathan Norris, managing director at Silicon Valley Bank, points to increased fund-raising by healthcare-focused venture capital firms and a surge by strategic investors in Series…

Piper Jaffray managing director Andrew Gitkin, head of West Coast biotech investment banking, delivers good news to attendees of OIS@AAO. Overall public markets are strong,…

Industry stalwart Jim Mazzo, global president, ophthalmology atd Zeiss, delivers his assessment of the state of innovation in ophthalmology.

Robert Dempsey, group vice president and head, global ophthalmics franchise, lays out Shire’s plans to roll out Xiidra worldwide. What are the challenges? Where will…

Jason Ehrlich, MD, PhD, the global head, clinical, of Genentech’s ophthalmology product development group, details the company’s current and future ophthalmology pipeline. He also looks…

Dirk Sauer, PhD, global development unit head of ophthalmology, lays out the next steps for Novartis’ potential AMD blockbuster. He also shares his views on…